Heron Therapeutics (HRTX) Fundamental Analysis: Revenue, Earnings & Valuation

5.51 / 10

Netural

The equity presents average fundamental picture (5.5/10). Strengths include Inventory turnover ratio and Cost of sales ratio (%), offset by weaknesses in Asset-MV. This merits balanced consideration.

Analysis Checks(9/10)

Revenue-MV

Value0.12

Score3/3

Weight29.97%

1M Return7.95%

Total operating revenue (YoY growth rate %)

Value7.36

Score2/3

Weight1.21%

1M Return0.41%

Inventory turnover ratio

Value0.57

Score3/3

Weight-1.42%

1M Return-0.48%

Profit-MV

Value0.62

Score2/3

Weight13.08%

1M Return4.10%

PB-ROE

Value-0.28

Score3/3

Weight38.77%

1M Return10.40%

Fixed assets turnover ratio

Value10.31

Score3/3

Weight2.19%

1M Return0.75%

Interest coverage ratio (EBIT / Interest expense) (%)

Value39.04

Score2/3

Weight-2.91%

1M Return-1.07%

Operating revenue (YoY growth rate %)

Value7.36

Score2/3

Weight2.01%

1M Return0.68%

Cost of sales ratio (%)

Value26.69

Score3/3

Weight4.45%

1M Return1.39%

Asset-MV

Value-0.72

Score1/3

Weight12.67%

1M Return3.90%

Is HRTX fundamentally strong?

HRTX scores 5.51/10 on fundamentals and holds a Fair valuation at present. Backed by its 0.00% ROE, -13.04% net margin, -7.46 P/E ratio, 10.51 P/B ratio, and -33.33% earnings growth, these metrics solidify its Netural investment rating.